Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles A Butts

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Translational Lung Cancer Research|March 26, 2015
Anti-tumor immune response in early stage non small cell lung cancer (NSCLC): implications for adjuvant therapyCharles A Butts
The Lancet. Oncology|May 17, 2014
VeriStrat validated in patients with non-small-cell lung cancerCharles A Butts
The Lancet. Oncology|January 5, 2016
TIME for a successful cancer vaccine in NSCLC?Charles A Butts, Randeep Sangha
Clinical Lung Cancer|April 14, 2009
Extending outcomes: epidermal growth factor receptor-targeted monoclonal antibodies in non-small-cell lung cancerAnil A Joy, Charles A Butts
The Oncologist|August 5, 2010
Adjuvant therapy in non-small cell lung cancer: current and future directionsRandeep Sangha, Julie Price, Charles A Butts
Interactive Cardiovascular and Thoracic Surgery|July 28, 2018
Is lobectomy superior to sublobar resection for early-stage small-cell lung cancer discovered intraoperatively?Simon R Turner, Charles A Butts, Brock J Debenham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2013
Reply to V. Lorusso et alCesare Gridelli, Ciro Gallo, Charles A Butts, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicityCarla M M Prado, Vickie E Baracos, Linda J McCargar, et al.
Clinical Lung Cancer|September 24, 2014
Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancerMichael P Chu, Sunita Ghosh, Carole R Chambers, et al.
Lung Cancer (Amsterdam, Netherlands)|December 17, 2013
Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancerJean-Louis Pujol, Robert Pirker, Thomas J Lynch, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Translational Lung Cancer Research|March 26, 2015
Anti-tumor immune response in early stage non small cell lung cancer (NSCLC): implications for adjuvant therapyCharles A Butts
The Lancet. Oncology|May 17, 2014
VeriStrat validated in patients with non-small-cell lung cancerCharles A Butts
The Lancet. Oncology|January 5, 2016
TIME for a successful cancer vaccine in NSCLC?Charles A Butts, Randeep Sangha
Clinical Lung Cancer|April 14, 2009
Extending outcomes: epidermal growth factor receptor-targeted monoclonal antibodies in non-small-cell lung cancerAnil A Joy, Charles A Butts
The Oncologist|August 5, 2010
Adjuvant therapy in non-small cell lung cancer: current and future directionsRandeep Sangha, Julie Price, Charles A Butts
Interactive Cardiovascular and Thoracic Surgery|July 28, 2018
Is lobectomy superior to sublobar resection for early-stage small-cell lung cancer discovered intraoperatively?Simon R Turner, Charles A Butts, Brock J Debenham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2013
Reply to V. Lorusso et alCesare Gridelli, Ciro Gallo, Charles A Butts, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicityCarla M M Prado, Vickie E Baracos, Linda J McCargar, et al.
Clinical Lung Cancer|September 24, 2014
Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancerMichael P Chu, Sunita Ghosh, Carole R Chambers, et al.
Lung Cancer (Amsterdam, Netherlands)|December 17, 2013
Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancerJean-Louis Pujol, Robert Pirker, Thomas J Lynch, et al.
Pageof 2